Regulus Therapeutics (RGLS)
(Real Time Quote from BATS)
$2.08 USD
+0.06 (2.97%)
Updated May 16, 2024 12:43 PM ET
2-Buy of 5 2
D Value D Growth D Momentum F VGM
Brokerage Reports
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 61 - 80 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Multiple Ascending Dose Study Initiated; 2019 Results; Reiterate Buy; Reducing PT to $1.50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q4/FY19 Uneventful; Ph1 MAD Completion And Topline Data Anticipated Mid:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Ph1 ADPKD MAD Re-initiated; Completion And Topline Results Anticipated Mid:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Outlook: RGLS4326 Progress Lifting Clin Hold and RG-012 Milestone from Sanofi
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
FDA Lifts Partial Clinical Hold; Second Tranche Financing Closed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Removal of Clinical Hold Removes Overhang; Runway Extended into 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Response to Clinical Hold Submitted; FDA Feedback Anticipated by Mid December
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Promising Preclinical RGLS4326 ADPKD Data at OTS Meeting
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
A Longstanding Pioneer in miRNAs; Initiating at Buy and $2.00 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Additional Regulatory Requirements to Reinitiate MAD Study for RGLS4326 Program
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Private Placement and Restructured Debt Extends Runway into Q1:20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L